Outcomes of Primary Simultaneous Pancreas-kidney Transplants by Induction Agent in the United States.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
02
09
2022
accepted:
20
09
2022
entrez:
21
11
2022
pubmed:
22
11
2022
medline:
22
11
2022
Statut:
epublish
Résumé
Long-term outcome data by induction type in simultaneous pancreas-kidney (SPK) is limited. Utilizing the Scientific Registry of Transplant Recipients, we examined all primary SPK transplants between 2000 and 2020, excluding crossmatch-positive recipients. We grouped recipients according to induction regimen into 3 groups: rabbit anti-thymocyte globulin (r-ATG) (n = 5678), alemtuzumab (n = 1199), and interleukin-2 receptor antagonist (IL-2RA; n = 1593). We analyzed the 10-y recipient and composite (kidney and pancreas) graft survival using the Kaplan-Meier survival function. Cox-proportion hazard models were generated to examine the association between induction type, the 10-y recipient, and graft survival. Models were adjusted for recipient age, sex, ethnicity, HLA-mismatch, diabetes type, dialysis dependency, cold-ischemia time, local versus imported organs, panel reactive antibody, steroid maintenance, and Pancreas Donor Risk Index. r-ATG was associated with the lowest 1-y kidney and pancreas rejection rates compared with other agents ( r-ATG use was associated with the lowest SPK rejection rates. Compared with r-ATG, alemtuzumab but not IL-2RA was associated with worse long-term death-censored SPK graft outcome. Our analysis supports the common use of r-ATG for induction in US primary SPK recipients.
Identifiants
pubmed: 36406900
doi: 10.1097/TXD.0000000000001412
pmc: PMC9671748
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1412Informations de copyright
Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
J Am Soc Nephrol. 2014 Jun;25(6):1349-56
pubmed: 24511120
Curr Opin Organ Transplant. 2015 Feb;20(1):94-102
pubmed: 25565444
Curr Pharm Des. 2020;26(28):3425-3439
pubmed: 32351176
Rev Diabet Stud. 2011 Spring;8(1):6-16
pubmed: 21720668
Exp Clin Transplant. 2021 May;19(5):397-404
pubmed: 34053419
Transplantation. 2009 Sep 27;88(6):810-9
pubmed: 19920781
Transplantation. 2004 Apr 27;77(8):1269-75
pubmed: 15114097
Transplant Proc. 2014 Jul-Aug;46(6):1928-31
pubmed: 25131073
Clin Transplant. 2002 Feb;16(1):60-8
pubmed: 11982617
Am J Transplant. 2008 Aug;8(8):1702-10
pubmed: 18694474
Tissue Antigens. 1990 Mar;35(3):118-27
pubmed: 2165283
Am J Transplant. 2010 Apr;10(4):837-845
pubmed: 20121753
Am J Transplant. 2006 Feb;6(2):331-9
pubmed: 16426317
Drugs. 2010 May 7;70(7):793-804
pubmed: 20426494
Transplant Proc. 2005 Oct;37(8):3531-4
pubmed: 16298651
Drugs. 2009 Jul 30;69(11):1483-512
pubmed: 19634926
Clin Transplant. 2013 Sep-Oct;27(5):693-700
pubmed: 23924066
Nephrol Dial Transplant. 2020 Apr 1;35(4):624-632
pubmed: 30202981
Sci Transl Med. 2011 Jun 15;3(87):87ra52
pubmed: 21677198
Med Arh. 2004;58(6):373-6
pubmed: 15648237
Am J Transplant. 2021 Feb;21 Suppl 2:138-207
pubmed: 33595197
J Immunol. 2013 Sep 1;191(5):2818-28
pubmed: 23913968
Am J Transplant. 2003 Jul;3(7):855-64
pubmed: 12814477
Clin Transplant. 2007 Sep-Oct;21(5):583-9
pubmed: 17845631